PEAK6 Investments’s CRISPR Therapeutics CRSP Stock Holding History

PEAK6 Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$14K	Buy	+297	New	+$15.1K	﹤0.01%	3221
2024 Q1	–	Sell	-175	Closed	-$12.5K	–	4141
2023 Q4	$11K	Sell	175 -23,353	-99%	-$1.29M	﹤0.01%	3930
2023 Q3	$1.07M	Buy	23,528 +13,768	+141%	+$711K	﹤0.01%	1799
2023 Q2	$548K	Sell	9,760 -40,256	-80%	-$2.28M	﹤0.01%	2139
2023 Q1	$2.26M	Sell	50,016 -221,829	-82%	-$10.8M	0.01%	1204
2022 Q4	$11.1M	Buy	+271,845	New	+$14.4M	0.06%	331
2022 Q3	–	Sell	-23,446	Closed	-$1.7M	–	5137
2022 Q2	$1.38M	Sell	23,446 -148,386	-86%	-$8.72M	﹤0.01%	2745
2022 Q1	$10.8M	Buy	171,832 +60,114	+54%	+$3.77M	0.02%	668
2021 Q4	$8.47M	Buy	111,718 +65,193	+140%	+$5.7M	0.02%	810
2021 Q3	$5.21M	Buy	+46,525	New	+$5.84M	0.01%	1130
2021 Q2	–	Sell	-39,944	Closed	-$4.86M	–	5222
2021 Q1	$4.87M	Buy	+39,944	New	+$6.03M	0.01%	1096

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PEAK6 Investments's CRSP Position: Q3 2024 in Review

PEAK6 Investments opened a new position in CRISPR Therapeutics (CRSP) in Q3 2024: 297 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #3221 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in CRSP as recently as Q4 2023.

PEAK6 Investments first reported a position in CRSP in Q1 2021 and has held it in 11 quarters since. The position peaked at $11.1M in Q4 2022. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

PEAK6 Investments held 297 shares of CRISPR Therapeutics worth $14K as of Q3 2024.
CRISPR Therapeutics was a new PEAK6 Investments position in Q3 2024.
CRISPR Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3221 holding.
PEAK6 Investments first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 11 quarters since.
PEAK6 Investments's CRISPR Therapeutics position peaked at $11.1M in Q4 2022.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.